What is Altimmune's net income?

Altimmune (ALT) reported net income of -$22.56M in Q1 2026.

How has Altimmune's net income changed year-over-year?

Altimmune's net income decreased by 15.3% year-over-year, from -$19.58M to -$22.56M.

What is the long-term trend for Altimmune's net income?

Over 4 years (2021 to 2025), Altimmune's net income has grown at a -2.4% compound annual growth rate (CAGR), from -$97.09M to -$88.09M.

What does net income mean?

The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Altimmune ALT Net Income

Net Income at other companies

Eli LillyLLY

$7.4B+168%

Merck & Co.MRK

-$4.24B-183%

Madrigal Pharmaceuticals, Inc.MDGL

-$94.39M-28.9%

Viking TherapeuticsVKTX

-$158.33M-247%

Wave Life SciencesWVE

-$26.09M+44.4%

MeiraGTx Holdings plcMGTX

-$46.31M-15.8%

Other financials

Income statement

See full

Revenue$26.0K+420%

Operating income-$24.2M-11.1%

EPS (diluted)-$0.18+30.8%

Balance sheet

See full

Cash & equivalents$97.6M+98.7%

Total debt$34.8M+14,092%

Total equity$284.0M+99.8%

Total assets$335.6M+113%

Cash flow

See full

Operating cash flow-$20.9M-24.4%

CapEx$21.0K—

Free cash flow-$21.0M—

Valuation

See full

Market cap$558.14M-2.1%

Enterprise value$495.27M-5.0%

P/S13,613.2×-24,380×

Profitability

See full

Operating margin-230,461%-82,087pp

Net margin-214,861%-76,057pp

FCF margin-17,806.8%-110,030pp

Returns & leverage

See full

Return on equity-42.7%-8.7pp

Debt / equity0.1×+0.1×

Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Altimmune's net income?: Altimmune (ALT) reported net income of -$22.56M in Q1 2026.
How has Altimmune's net income changed year-over-year?: Altimmune's net income decreased by 15.3% year-over-year, from -$19.58M to -$22.56M.
What is the long-term trend for Altimmune's net income?: Over 4 years (2021 to 2025), Altimmune's net income has grown at a -2.4% compound annual growth rate (CAGR), from -$97.09M to -$88.09M.
What does net income mean?: The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.